Seborrheic Dermatitis in the United States: Stable National Rates With Marked State‐Level Variation, 2010–2021

Le résumé fourni par la source

A.G. is an unpaid official Senior Collaborator for IHME/GBD. He serves as an Associate Editor for the Journal of Investigative Dermatology and the International Journal of Dermatology, a Physician Editor for VisualDx, a member of the Board of Directors for the Biology of Skin Foundation, and a Medical Director at AbbVie. D.G.C. has served as a consultant, speaker, and/or investigator for AbbVie, Alumis, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Castle, Dermavant/Organon, DermTech, Eli Lilly, Galderma, Johnson and Johnson, Journey, KOWA, Pfizer, Regeneron, and Sanofi, UCB. C.G.B. has served as an investigator for AbbVie, Almirall, Apogee, Daiichi Sankyo, LEO Pharma, Ortho Dermatologics, Sun Pharma, Takeda, Timber, and Palvella; a consultant for AbbVie, Almirall, Alumis, Amgen, Apogee, Arcutis, Botanix, Connect BioPharma, Dermavant, Eli Lilly, EPI Health/Novan, Galderma, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, Teladoc, Triveni, and UCB. L.S., H.A., and M.G. declare no information. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.